Tubidy
    Highlights on Lu-PSMA-617 in taxane-naive patients with mCRPC: The PSMAfore study

    Highlights on Lu-PSMA-617 in taxane-naive patients with mCRPC: The PSMAfore study

    03:24 |
    Download MP3

    Related Videos

    ESCAT - How to classify genomic alterations according level of actionability 4:22

    ESCAT - How to classify genomic alterations according level of actionability

    European Society for Medical Oncology (ESMO) 2023 - Presidential Symposium / Abstract #LBA5 7:42

    European Society for Medical Oncology (ESMO) 2023 - Presidential Symposium / Abstract #LBA5

    ESMO OncologyPRO - Intro by Prof. A. MATIKAS 1:31

    ESMO OncologyPRO - Intro by Prof. A. MATIKAS

    ESMO Sarcoma and Rare Cancers 2025: Why you should submit your abstract 1:48

    ESMO Sarcoma and Rare Cancers 2025: Why you should submit your abstract

    MAP 2024: shaping the future of precision oncology 1:45

    MAP 2024: shaping the future of precision oncology

    Claudia Cardone and Andrea Koulouris on how to prepare for the ESMO Examination 0:59

    Claudia Cardone and Andrea Koulouris on how to prepare for the ESMO Examination

    ESMO Immuno-Oncology 2024 Congress Experts in the field invite you to share your research. 1:42

    ESMO Immuno-Oncology 2024 Congress Experts in the field invite you to share your research.

    European Society for Medical Oncology (ESMO): Partnering to eliminate cervical cancer 1:37

    European Society for Medical Oncology (ESMO): Partnering to eliminate cervical cancer

    European Society for Medical Oncology (ESMO) 2023 - Abstracts #2362MO and #2359O 9:07

    European Society for Medical Oncology (ESMO) 2023 - Abstracts #2362MO and #2359O

    ESMO Course in medical oncology for medical students: why should you apply? 3:30

    ESMO Course in medical oncology for medical students: why should you apply?

    ESMO Congress 2023 Virtual Platform 0:38

    ESMO Congress 2023 Virtual Platform

    ESMO Asia Congress 2024: multidisciplinary oncology in the Asian region 1:37

    ESMO Asia Congress 2024: multidisciplinary oncology in the Asian region

    How to determine best first line treatment for ovarian cancer? 4:33

    How to determine best first line treatment for ovarian cancer?

    ESMO Immuno-Oncology 2024 Congress M. Maio, A. Marabelle and I. Svane invite you to attend 2:00

    ESMO Immuno-Oncology 2024 Congress M. Maio, A. Marabelle and I. Svane invite you to attend

    BRAF Mutations Across Cancers 5:14

    BRAF Mutations Across Cancers

    Highlights on Lu-PSMA-617 in taxane-naive patients with mCRPC: The PSMAfore study 3:25

    Highlights on Lu-PSMA-617 in taxane-naive patients with mCRPC: The PSMAfore study

    ESMO OncologyPRO - Presentation by Dr. E. SMYTH 1:53

    ESMO OncologyPRO - Presentation by Dr. E. SMYTH

    WHO-ESMO Collaboration Plan 2024-2026 7:56

    WHO-ESMO Collaboration Plan 2024-2026

    ESMO OncologyPRO - Intro by Dr. E. SMYTH 1:46

    ESMO OncologyPRO - Intro by Dr. E. SMYTH

    Introducing the ESMO Magnitude of Clinical Benefit Scale 0:58

    Introducing the ESMO Magnitude of Clinical Benefit Scale